Myxoma virus (MYXV) is a member of the Poxviridae family and prototype for the genus Leporipoxvirus. It is pathogenic only for European rabbits, in which it causes the lethal disease myxomatosis, and two North American species, in which it causes a less severe disease. MYXV replicates exclusively in the cytoplasm of the host cell. Although not infectious in humans, its genome encodes proteins that can interfere with or modulate host defense mechanisms; it is able to productively infect a number of human cancer cell lines, but not normal human cells, and has also been shown to increase survival time in mouse models of human glioma. These characteristics suggest that MYXV could be a viable therapeutic agent, e.g., in anti-inflammatory or anti-immune therapy, or as an oncolytic agent. MYXV is also an excellent model for poxvirus biology, pathogenesis, and host tropism studies. It is easily propagated in a number of cell lines, including adherent cells and suspension cultures, and minimal purification is required to provide a stock for in vivo and in vitro studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901999PMC
http://dx.doi.org/10.1002/9780471729259.mc14a01s17DOI Listing

Publication Analysis

Top Keywords

myxoma virus
8
cell lines
8
virus propagation
4
propagation purification
4
purification quantification
4
quantification storage
4
storage myxoma
4
myxv
4
virus myxv
4
myxv member
4

Similar Publications

Modified Vaccinia Virus Ankara Selectively Targets Human Cancer Cells With Low Expression of the Zinc-Finger Antiviral Protein.

J Med Virol

January 2025

National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.

Oncolytic viruses are emerging as promising cancer therapeutic agents, with several poxviruses, including vaccinia virus (VACV) and myxoma virus, showing significant potential in preclinical and clinical trials. Modified vaccinia virus Ankara (MVA), a laboratory-derived VACV strain approved by the FDA for mpox and smallpox vaccination, has been shown to be incapable of replicating in human cells unless zinc finger antiviral protein (ZAP) is repressed. Notably, ZAP deficiency is prevalent in various cancer types.

View Article and Find Full Text PDF

Testing Oncolytic Myxoma Virus in Immunocompetent Mouse Model for Cancer Therapy.

Methods Mol Biol

December 2024

Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.

Oncolytic viruses (OVs) have emerged as a class of novel cancer immunotherapeutic. Members of both DNA and RNA viruses developed as OVs for treating diverse types of human cancers. Preclinical research assessing immunotherapeutic efficacy is an essential step toward further development of these OVs.

View Article and Find Full Text PDF

Evaluation of dried blood spots for serological surveys of myxoma and rabbit hemorrhagic disease viruses in their wild reservoir.

Prev Vet Med

January 2025

CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos, InBIO Laboratório Associado, Universidade do Porto, Campus de Vairão, Vairão 4485-661, Portugal; BIOPOLIS Program in Genomics, Biodiversity and Land Planning, CIBIO, Campus de Vairão, Vairão 4485-661, Portugal; Estação Biológica de Mértola (EBM), CIBIO, Praça Luís de Camões, Mértola 7750-329, Portugal. Electronic address:

Article Synopsis
  • Myxoma (MYXV) and rabbit hemorrhagic disease (RHDV) viruses are significant threats to European rabbits, which are now considered 'Endangered' in their native habitat.
  • The study focused on evaluating the effectiveness of dried blood spots (DBS) for serological surveys of these viruses in European rabbits by comparing DBS to traditional serum samples.
  • Results showed a high level of agreement between the two methods, with DBS demonstrating strong diagnostic sensitivity and perfect specificity for both MYXV and RHDV, confirming its viability for monitoring these diseases in the wild rabbit population.
View Article and Find Full Text PDF

Treatment of glioblastoma is ineffective. Myx-M011L-KO/EGFP, a myxoma virus actively inducing apoptosis in BTICs linked to recurrence, offers innovative treatment. We loaded this construct into adipose-derived stem cells (ADSCs) to mitigate antiviral host responses and enable systemic delivery.

View Article and Find Full Text PDF

Cytokine therapy represents an attractive option to improve the outcomes of cancer patients. However, the systemic delivery of these agents often leads to severe immune-related toxicities, which can prevent their efficient clinical use. One approach to address this issue is the use of recombinant oncolytic viruses to deliver various cytokines directly to the tumor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!